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O
ver 300,000 patients throughout the
world are now receiving recombinant
human erythropoietin (rHuEpo) for
the treatment of anemia of renal failure, and
more than 95% of them respond to rHuEpo if
adequate doses are given.1 Treatment is cost-
effective to the extent that a standard mainte-
nance dose of ≤ 100 U/kg/week abolishes a
transfusion requirement of 2-3 units of blood
per month and improves the quality of life in
severely anemic patients.
Outside the uremia setting only a portion of
anemic patients benefit from rHuEpo treat-
ment.2,3 Responsive individuals range from
about 16% in myelodysplastic syndromes to
nearly 70% in multiple myeloma, and there is a
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Background. Since only a portion of anemic patients outside the uremia setting benefit from erythro-
poietin treatment, a reliable means of predicting potential responders and nonresponders would be
very useful.
Materials and Methods. We retrospectively reviewed the clinical records of 58 patients with refracto-
ry anemia associated with various malignant disorders who had been treated with subcutaneous
rHuEpo. The starting rHuEpo dose was 375 U/kg/week for 4 weeks, and was increased to 750
U/kg/week for another 4 weeks if no response was observed. Response was defined as a Hb increase ≥ 2
g/dL with no need for blood transfusion. We examined the value of various laboratory parameters
(baseline levels, 2-week and 4-week changes) as predictors of response. Endogenous erythropoietin
production was evaluated by its serum level and erythroid activity was assessed through reticulocyte
count and circulating transferrin receptor.
Results. Forty-eight individuals were evaluable, 58% of whom responded to rHuEpo within 8 weeks.
Multiple regression analysis showed that 53% of the variation in the 8-week Hb concentration was
explained by variations in baseline serum erythropoietin and the 2-week change in serum transferrin
receptor (p < 0.001). Based on these two parameters, response prediction in individual patients would
have resulted in a sensitivity of 96%, a specificity of 79% and an overall accuracy of 88%. In addition,
58% of the variation in the 8-week Hb was explained by variations in the 4-week changes in Hb and
reticulocyte count (p < 0.001). Utilizing these latter parameters and baseline serum erythropoietin,
response prediction in individual patients would have resulted in a sensitivity of 92%, a specificity of
82% and an overall accuracy of 88%.
Conclusions. This retrospective analysis suggests that response to rHuEpo can be reasonably predict-
ed by pretreatment serum erythropoietin together with early changes in simple laboratory parameters.
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relationship between defective endogenous ery-
thropoietin production and the likelihood of
response to rHuEpo.3
Recombinant erythropoietin is an expensive
drug and cost containment is a major issue in
health care policy today. A reliable means of pre-
dicting potential responders and nonresponders
would be clinically useful in nonrenal condi-
tions. Therefore we retrospectively reviewed the
clinical records of 58 neoplastic patients treated
with rHuEpo. The aim of this work was to iden-
tify predictors of response and define a patient-
oriented rather than a disease-oriented approach
to rHuEpo treatment of nonrenal anemia.
Patients and Methods
Patients
The use of rHuEpo in the treatment of refrac-
tory anemia associated with hematological dis-
orders and solid tumors was approved by the
ethical committee of the Department of Internal
Medicine and Medical Therapy, University of
Pavia Medical School, Pavia, Italy. All patients
gave written informed consent.
We delivered rHuEpo to 58 consecutive sub-
jects with refractory anemia associated with var-
ious disorders and Hb levels < 10 g/dL. Nine
patients suffered from myelodysplastic syn-
drome (MDS), 18 from multiple myeloma, 11
from non-Hodgkin’s lymphoma, and 20 from
solid tumors. 
The rHuEpo used in the study was provided
by Boehringer Mannheim GmbH, Mannheim,
Germany. The treatment protocol was a modifi-
cation of that previously adopted in a phase I-II
clinical trial.4,5 The drug was administered sub-
cutaneously once a day, 5 d per week (Monday
to Friday) on an outpatient basis; it was self-
administered or given by relatives or private
nurses. The starting rHuEpo dose was 375
U/kg/week for 4 weeks, and was increased to
750 U/kg/week for another 4 weeks if no
response was observed. In each case dosage was
adjusted so as to allow the optimal utilization of
each single vial in order not to waste the prod-
uct. Response was defined as a Hb increase ≥ 2
g/dL with no need for blood transfusion.
Laboratory investigations
Complete blood counts were performed
weekly. Reticulocyte count was corrected to
account for anemia,4 and body iron status was
evaluated by measuring serum iron, transferrin
saturation and serum ferritin.5 Oral iron supple-
mentation (ferrous iron sulphate, 100 mg/day)
was given routinely except to patients whose
baseline serum iron was > 150 µg/dL and/or
transferrin saturation > 60%.
Circulating erythropoietin levels were mea-
sured by a commercially available radioimmu-
noassay.6 To define erythropoietin levels as
appropriate or inappropriate for a given degree
of anemia, an exponential regression of serum
erythropoietin versus Hct was determined in
reference subjects and the 95% confidence limits
were defined.6 Based on this regression, the
observed/predicted log(epo) ratio (O/P ratio)
was derived for each sample. The O/P ratio
averaged 1.00±0.11 in reference subjects (95%
confidence interval: 0.80-1.19).
Serum transferrin receptor (TfR), the level of
which provides an estimate of erythroid marrow
activity, was measured by an enzyme-linked
polyclonal antibody assay.6 TfR levels in 165
normal control subjects were 5.0±1.1 mg/L,
with 95% confidence limits ranging from 2.9 to
7.1 mg/L.
Statistical analysis
Data were stored, analyzed and reported with
the packages Statistica/Mac (StatSoft.™, Tulsa,
OK), Exstatix™ (Select Micro Systems Inc.,
Yorktown Heights, NY) and DeltaGraph™ Pro 3
(DeltaPoint Inc., Monterey, CA), all run on a
Macintosh Quadra 650 (Apple Computer Inc.,
Cupertino, CA) personal computer. Results
were expressed as mean±1 standard deviation
(SD) unless otherwise stated. The Student’s t-
test and/or the F test (analysis of variance) were
used to evaluate the probability of any signifi-
cant difference between groups. Chi-square
analysis was utilized to determine whether clas-
sifications of two different parameters were
related or not. Multiple regression analysis was
used to study the value of various laboratory
parameters (baseline levels, 2-week and 4-week
changes) as predictors of response to rHuEpo.
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Definitions
The following definitions were adopted in
relation to response prediction:
true-positive predictions
sensitivity =




all patients who would





positive predictive value =
true-positive predictions 
true + false positive predictions
negative predictive value =
true-negative predictions
true + false negative predictions
Results
There were ten withdrawals, so that a total of
48 subjects were evaluable. Fifty-eight percent of
patients (28/48) achieved the defined response
within 8 weeks of treatment. Their clinical and
laboratory characteristics are summarized in
Table 1.
Endogenous erythropoietin production and
response to rHuEpo
There was an inverse relationship between the
8-week ∆Hb (where ∆ indicates the change
with respect to the baseline value) and the base-
line serum erythropoietin O/P ratio (r = –0.57;
p<0.001) (Figure 1). 
In addition, 25/31 patients with serum ery-
thropoietin < 100 mU/mL responded, whereas
only 3/17 with values ≥ 100 mU/mL did (2 =
10.1; p < 0.01).
Relationship between response and changes in
Hb, reticulocyte count and serum transferrin
receptor after 2 and 4 weeks
The Hb increment after 8 weeks was directly
related to the 2-week change in TfR (r = 0.68; p
< 0.001) (Figure 2); 24/26 patients showing a 2-
week TfR increment ≥ 25% responded to
rHuEpo within 8 weeks, whereas only 4/22 with
a ∆TfR < 25% did (2 = 16.3; p < 0.001). Hb
changes after 2 weeks were weakly related to the
Hb increment after 8 weeks (r = 0.38; p < 0.01),
whereas there was no relationship between this
latter parameter and changes in reticulocyte
count after 2 weeks.
The Hb increment after 8 weeks was very
closely related not only to the 4-week change in
TfR (r = 0.70; p < 0.001) but also to the 4-week
change in reticulocyte count (r = 0.70; p <
0.001) and in Hb level (r = 0.68; p < 0.001)
(Figure 3).
Multiple regression analysis for estimating the
value of various laboratory parameters (baseline
levels, 2-week and 4-week changes) as predictors
of response to rHuEpo
Multiple regression analysis using baseline
values and 2-week changes showed that the
baseline O/P ratio and the 2-week change in TfR
were independent predictors of response to
Condition Hb Retic Serum Serum Serum O/P ratio Responders
(pt no.) g/dL % iron TfR Epo
µg/dL mg/L mU/mL
Myelodysplastic 8.2± 1.3 0.9± 0.4 161± 52 3.39± 1.31 350± 423 1.00± 0.23 3/9
syndromes (n=9)
Multiplemyeloma (n=17) 8.7± 0.7 1.2± 0.6 99± 49 4.6± 2.7 95± 85 0.81± 0.18 11/17
Non-Hodgkin’s 8.5± 1.1 1.5± 1.0 78± 33 6.0± 2.7 142± 104 0.90± 0.16 3/8
lymphoma (n=8)
Solid tumors (n=14) 9.1± 0.8 1.5± 0.7 71± 36 4.8± 2.0 87± 94 0.82± 0.19 11/14
Table 1. Patient char-
acteristics and
response to rHuEpo
(mean value ± 1 SD).
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rHuEpo. In fact, 53% of the variation in the 8-
week change in Hb was explained by variations
in these two parameters (adjusted multiple-r =
0.73; p < 0.0001).
Regression of 8-week ∆Hb versus baseline val-
ues and 4-week changes showed that 58% of the
variation in the 8-week change in Hb was
explained by variations in the 4-week changes in
reticulocyte count and Hb level (adjusted multi-
ple-r = 0.75; p < 0.0001).
Algorithms for predicting response to rHuEpo
Two algorithms for predicting response to




































































Serum erythropoietin O/P ratio
Figure 1. Relationship between the change in Hb after 8 weeks of rHuEpo






































































2-week change in TfR (%)
Figure 2. Relationship between the change in Hb after 8 weeks of rHuEpo






























































































































4-week change in reticulocyte count (109/L)
Figure 3. Relationship between the change in Hb after 8 weeks of rHuEpo
treatment and the 4-week change in Hb level (top) or reticulocyte count
(bottom).
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be elaborated.
The first one was developed by using the base-
line serum erythropoietin, taken as an indicator
of the adequacy of endogenous erythropoietin
production, and the 2-week TfR increment,
taken as an indicator of early response (Figure
4). Utilizing this algorithm would have resulted
in a sensitivity of 96%, a specificity of 79% and
an overall accuracy of 88%. Positive predictive
value would have been 82% and negative pre-
dictive value 95%.
The second algorithm was developed by using
the baseline serum erythropoietin, taken as an
indicator of the adequacy of endogenous ery-
thropoietin production, and the 4-week changes
in Hb and reticulocytes, taken as indicators of
early response (Figure 5). Utilizing this algo-
rithm would have resulted in a sensitivity of
92%, a specificity of 82% and an overall accura-
cy of 88%. Positive predictive value would have
been 86% and negative predictive value 90%.
It should be noted, however, that intensive
chemotherapy may transiently elevate serum
erythropoietin.7 The predictive power of the
above algorithms could therefore be altered in
patients receiving chemotherapy immediately
before and/or during the initial phase of
rHuEpo treatment. Excluding individuals under
cyclic chemotherapy would have raised both
specificity and overall accuracy. For example,
the accuracy of the first step in both predictive
algorithms would have increased from 82 to
100%.
Discussion
In the present study, as well as in previous
reports,8-10 defective endogenous erythropoietin
production was found to be a major predictor of
response to rHuEpo. This observation is in
keeping with the biology of erythropoietin,
which expands erythropoiesis mainly by pre-
Step 1:
serum erythropoietin




∆TfR ≥ 25% at 









Figure 4. Algorithm to predict response to rHuEpo treatment in patients
with anemia of malignancy based on serum erythropoietin and 2-week
change in serum transferrin receptor (TfR).
Utilizing this algorithm would have resulted in a sensitivity of 96%, a
specificity of 79% and an overall accuracy of 88%. Positive predictive
value would have been 82% and negative predictive value 95%.
Step 1:
serum erythropoietin




∆Hb ≥ 1 g/dL 
or∆reticulocyte count
≥ 40 x 109/L at









Figure 5. Algorithm to predict response to rHuEpo treatment in patients
with anemia of malignancy based on serum erythropoietin and 4-week
changes in Hb level and reticulocyte count.
Cutoffs for ∆Hb and ∆reticulocyte count were derived from analysis of
data reported in Figure 3. Utilizing this algorithm would have resulted in a
sensitivity of 92%, a specificity of 82% and an overall accuracy of 88%.
Positive predictive value would have been 86% and negative predictive
value 90%.
venting apoptosis of late erythroid progenitor
cells and proerythroblasts.11,12 The erythroid
hormone is therefore unlikely to increase red
cell production when endogenous production is
physiologically elevated and nearly all available
progenitors are already surviving and differenti-
ating to immature red cells. By contrast, when
endogenous erythropoietin levels are inappro-
priately low for the degree of anemia,6 adminis-
tration of pharmacological doses of erythropoi-
etin may prevent apoptosis of considerable
numbers of erythroid progenitors and increase
red cell production.
Several reports point to the use of a serum ery-
thropoietin threshold of ≤ 100 mU/mL to pre-
dict response to rHuEpo. In the study by Stenke
et al.8 on the use of rHuEpo in the treatment of
myelodysplastic syndromes, all responders but
one had serum erythropoietin levels lower than
100 mU/mL. Rose et al.13 treated 100 MDS
patients, 28% of whom responded to rHuEpo.
Overall, 86% (24/28) of responders had baseline
erythropoietin levels ≤ 100 mU/mL. Hellström-
Lindberg14 analyzed 205 MDS patients from 17
published reports; her meta-analysis confirms
that baseline serum erythropoietin is crucial for
response to rHuEpo, since no patient with serum
levels > 200 mU/mL benefited from rHuEpo.
Cazzola et al.10 used rHuEpo in the treatment of
anemia associated with multiple myeloma and
non-Hodgkin’s lymphoma. In patients receiving
500 U/kg/week or more, baseline serum erythro-
poietin proved to be the best predictor of
response; about three quarters of subjects with
levels ≤ 100 mU/mL responded to treatment,
whereas less than one fifth of those with levels
>100 mU/mL did so.
Although the use of the O/P ratio as a mea-
sure of the adequacy of endogenous erythropoi-
etin production would have been more rigor-
ous, adopting a cutoff for serum erythropoietin
of 100 mU/mL in the first step of the predictive
algorithm proved to be clinically useful, at least
for patients with Hb levels < 10 g/dL (Figures 4
and 5). The positive predictive value of this sim-
ple parameter was 82%, but increased to 100%
when those patients who had received chemo-
therapy immediately before measurement were
excluded. This implies that serum erythropoi-
etin should not be assayed immediately after
administration of intensive chemotherapy.
There are only a few exceptions to the rule of a
low endogenous erythropoietin level as a pre-
requisite for response to rHuEpo, one being rep-
resented by patients suffering from pure red cell
aplasia.15
Since some patients with serum erythropoi-
etin < 100 mU/mL may nonetheless be unre-
sponsive to rHuEpo (e.g. 6/21 in the present
study and 37/72 in the report by Rose et al.13)
there is a need for indicators of early response
which allow clinicians to decide whether to con-
tinue or terminate rHuEpo therapy. The second
parameter we employed to develop the first pre-
dictive algorithm (Figure 4) was the 2-week
change in circulating transferrin receptor, taken
as an indicator of early response. Serum trans-
ferrin receptor is a measure of total marrow ery-
thropoietic activity.4,6 Beguin et al.16 already
demonstrated the usefulness of this parameter
for early prediction of response to rHuEpo in
patients with anemia of renal failure. In their
study, when the 2-week TfR increment was
greater than 20%, the response rate was 87%;
when the TfR increment was less than 20%, the
response rate was 48%. In the present study, the
change in serum transferrin receptor after 2
weeks proved to be a valuable factor for predict-
ing response to rHuEpo. Only one out of the 23
patients showing a 2-week ∆TfR ≥ 25% failed to
achieve the defined response.
Previous studies had documented that the
change in Hb after 2 weeks was a powerful pre-
dictor of responsiveness to rHuEpo treatment;9,10
however, this parameter may be useless in
patients receiving transfusions and/or concomi-
tant chemotherapy. Changes in the reticulocyte
count after 2 weeks may simply reflect the out-
put of shift reticulocytes and not a true expan-
sion of erythropoiesis.17 By contrast, a 4-week
increment in reticulocyte count of ≥ 40109/L
was found to correlate positively with response
to rHuEpo in cancer anemia.18 Increments in
high-fluorescence reticulocytes were found to
predict response to rHuEpo in myelodysplastic
syndromes.1 9 In the present study, 4-week
changes in both Hb level and reticulocyte count
proved to correlate with response (Figure 3) and
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to be useful for developing a simple predictive
algorithm (Figure 5). Although changes in
serum transferrin receptor assay appear to be
the best indicator of response to rHuEpo after 2
weeks, changes in hemoglobin and reticulocyte
count after 4 weeks seem to be equally useful.
Unlike the TfR assay, these latter parameters are
widely available and this may justify two addi-
tional weeks of treatment; one full month of
rHuEpo treatment may also be more reasonable
in the patient’s eyes.
Erythropoietin is currently approved only for
specific conditions, but one of the duties of a
physician is to be able to move from public poli-
cy implemented for the average patient to one
that serves the individual patient’s needs.3 We
believe that rHuEpo should be provided to all
patients who can benefit from it, regardless of
whether the basic disorder is an approved con-
dition or not. As summarized in Table 2, a num-
ber of factors predicting response to rHuEpo
have now been identified. Utilizing predictive
algorithms may allow a patient-oriented rather
than a disease-oriented approach to rHuEpo
treatment of nonrenal anemia. Clearly these
algorithms need to be refined (for example, the
timing of both treatment and laboratory investi-
gations with respect to chemotherapy is critical)
and validated in future prospective studies.
While discussing this work with colleagues,
some of them looked at our algorithms with a
certain disdain. We realize that many physicians
will argue that these are just statistical values
and that their own patients might be among the
few who will respond despite all the negative
predictions (Figures 4 and 5). Some of them will
also state that they will not discontinue rHuEpo
treatment in the individual patient until there is
a definite lack of response. The question is: how
long should treatment be continued before it
can be decided with certainty that the individual
patient is unresponsive? More generally, the
problem can be seen from the patient’s or the
community’s point of view. If the latter is to pay
for the cost of treatment, it appears wise to
adopt criteria that might penalize very few indi-
viduals but help many, many others.
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